Table 1.
Characteristics of Studies Included for Meta‐Analysis
| First Author (Year) | Prior AP Therapy | No. of Patients, N | Median Age, y | Female, % | Mean Serum Glucose, mg/dL | Mean NIHSS | Onset to Treatment Time, min | AP Agents | sICH Definition | Outcome Follow‐up Time, d |
|---|---|---|---|---|---|---|---|---|---|---|
| Xian29 (2016) | Yes | 38 844 | 73.7 | 49.7 | 138.6 | 11.5 | 138 | A/C/AC/AD/O | NAa 0–36 h | At discharge |
| No | 46 228 | 67.2 | 51.4 | 135.6 | 11.2 | 138 | ||||
| Meseguer27 (2015) | Yes | 191 | 74.5 | 43.4 | 124 | 12 | 160 | NA | E 0–24 h | 90 |
| No | 375 | 65.8 | 46.1 | 119 | 11 | 160 | ||||
| Watson‐Fargie28 (2015) | Yes | 132 | NA | NA | NA | NA | NA | NA | E/N 0–24 h | NA |
| No | 216 | |||||||||
| Lindley26 (2015) | Yes | 775 | NA | NA | NA | NA | NA | A/C/D/O | NA 0–7 d | 7 |
| No | 740 | |||||||||
| Pan25 (2015) | Yes | 157 | 66.0 | 40.8 | 140.7 | 12 | 168 | A/C/AC/O | E/N/S24–36 h | 90 |
| No | 951 | 62.7 | 38.3 | 138.9 | 11 | 168 | ||||
| Frank23 (2013) | Yes | 727 | NA | NA | NA | NA | NA | SI/DU | E 0–4 d | NA |
| No | 1826 | |||||||||
| Meurer24 (2013) | Yes | 388 | 74 | 47.7 | 137 | 13 | 148 | NA | N 0–10 d | NA |
| No | 442 | 65 | 46.2 | 126 | 12 | 151 | ||||
| Šaňák21 (2012) | Yes | 56 | 69.8 | 50.0 | NA | 16 | 154.7 | A/C/AD | S 0–24 | NA |
| No | 90 | 65.8 | 43.3 | 15 | 157.6 | |||||
| Ibrahim20 (2010) | Yes | 95 | 71.5 | 51.3 | NA | 16.8 | NA | A/C/AC/AD | S 0–72 h | 90 |
| No | 180 | 68.3 | 33.8 | 15.8 | ||||||
| Dorado19 (2010) | Yes | 72 | 70.5 | NA | NA | NA | NA | A/C/AC/O | E 0–36 h | 90 |
| No | 163 | 66.9 | ||||||||
| Diedler18 (2010) | Yes | 3782 | 71 | 41.2 | 118 | 12 | 140 | A/C/AC/AD/O | E/N/S 0–7 d | 90 |
| No | 7954 | 66 | 35.1 | 116 | 12 | 140 | ||||
| Hermann17 (2009) | Yes | 36 | 71 | NA | NA | NA | NA | A/C/AC/AD | S 12–36 h | NA |
| No | 27 | 67 | ||||||||
| Cucchiara16 (2009) | Yes | 337 | NA | NA | NA | NA | NA | SI/AC/AD/O | NA 0–36 h | NA |
| No | 628 | |||||||||
| Bluhmki15 (2009) | Yes | 130 | NA | NA | NA | NA | NA | NA | N 22–36 h | 90 |
| No | 288 | |||||||||
| Uyttenboogaart13 (2008) | Yes | 89 | 73 | 48.4 | 115 | 12 | 165 | A/C/D/AD | S 0–36 h | 90 |
| No | 212 | 66 | 47.2 | 115 | 13 | 175 | ||||
| Bravo12 (2008) | Yes | 137 | 72.2 | 35 | 137 | 14 | 148.5 | A/C/D/O | E 24–36 h | NA |
| No | 468 | 66.6 | 43.8 | 134 | 15 | 151.1 | ||||
| Martí‐Fàbregas11 (2007) | Yes | 49 | NA | NA | NA | NA | NA | NA | NA 24–36 h | NA |
| No | 298 | |||||||||
| Schmülling10 (2003) | Yes | 95 | 66 | NA | NA | 13 | NA | A/O | N 36–48 h | 90 |
| No | 202 | 62 | 10 | |||||||
| Tanne9 (2002) | Yes | 386 | NA | NA | NA | NA | NA | A/O | N 0–36 h | NA |
| No | 813 |
AP indicates antiplatelet; NIHSS, National Institutes of Health Stroke Scale; sICH, symptomatic intracranial hemorrhage; A, aspirin; C, clopidogrel; AC, aspirin–clopidogrel; AD, aspirin–dipyridamole; O, other antiplatelet medications; NA, not available; E, ECASS II, Second European‐Australasian Acute Stroke Study3; N, NINDS, National Institute of Neurological Disorders and Stroke rt‐PA Stroke Study Group2; D, dipyridamole; S, SITS‐MOST, Safe Implementation of Thrombolysis in Stroke‐Monitoring Study4; SI, single; DU, dual.
a
sICH definition was recorded as NA if it did not accord with any of the 3 definitions: ECASS II, SITS‐MOST, and NINDS.